The prestigious Endpoints 11 recognizes eleven private biotech companies distinguished by rapid innovation across diverse modalities including AI-driven drug discovery, in vivo CAR-T therapies, autoimmune T-cell engagers, macrocycle oral biologics, and RNA therapeutics. Highlighted startups such as Chai Discovery, Umoja Biopharma, Candid Therapeutics, and others, have collectively raised billions in funding and represent the vanguard of biotech innovation poised to transform disease treatment landscapes globally.